| |
None
|
Healthy T cells
|
JMML T cellsa
|
|---|
| |
Mock 1:1
|
CAR 1:1
|
Mock 1:1
|
CAR 1:1
|
|---|
|
Patient no. 5
| | | | | |
|
CD34+ cells (×104)
|
8.85 ± 0.44
|
7.75 ± 0.62
|
2.57 ± 0.33
|
6.73 ± 0.52
|
0.88 ± 0.04
|
|
CD34+CD38− cells (×104)
|
3.78 ± 0.19
|
3.20 ± 0.26
|
0.04 ± 0
|
2.80 ± 0.22
|
0 ± 0
|
|
CD34+CD38+ cells (×104)
|
5.07 ± 0.25
|
4.56 ± 0.37
|
2.53 ± 0.33
|
3.93 ± 0.30
|
0.88 ± 0.04
|
|
Patient no. 6
| | | | | |
|
CD34+ cells (×104)
|
9.38 ± 0.77
|
8.15 ± 0.67
|
1.91 ± 0.17*
|
7.50 ± 0.49
|
2.50 ± 0.20*
|
|
CD34+CD38− cells (×104)
|
5.45 ± 0.45
|
4.65 ± 0.38
|
0.30 ± 0.03*
|
4.52 ± 0.30
|
0.55 ± 0.04*
|
|
CD34+CD38+ cells (×104)
|
3.93 ± 0.32
|
3.50 ± 0.29
|
1.62 ± 0.15*
|
2.98 ± 0.19
|
1.96 ± 0.16*
|
-
Patient no. 5 monosomy 7, patient no. 6 trisomy 8 plus PTPN11 mutation, GMR GM-CSF receptor, CAR chimeric antigen receptor, JMML juvenile myelomonocytic leukemia, SCF stem cell factor, TPO thrombopoietin
-
*
p < 0.0001, significant different from mock T cells
-
aT cells were obtained from patient no. 4 with PTPN11 and SETBP1 mutations after unrelated CBT
